Keron Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 28.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 20.60 Cr
as on 16-11-2024
- Company Age 12 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.75 Cr
as on 16-11-2024
- Revenue -77.56%
(FY 2023)
- Profit 14.10%
(FY 2023)
- Ebitda 29.28%
(FY 2023)
- Net Worth -25.86%
(FY 2023)
- Total Assets -17.53%
(FY 2023)
About Keron Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 28.00 Cr and a paid-up capital of Rs 20.60 Cr.
The company has closed loans amounting to ₹1.75 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Shailesh Mishra, Manoj Jain, Ghazi Alabdulrazzak, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24297UR2012PTC000295
- Company No.
000295
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jun 2012
- Date of AGM
23 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Dehradun, Uttarakhand, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Keron Lifesciences Private Limited offer?
Keron Lifesciences Private Limited offers a wide range of products and services, including Hand Sanitizers & Personal Hygiene, Antiseptic Liquid & Cream, Pain Relief Drugs & Pharmaceuticals, Diclofenac, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Cardiovascular Drugs & Medication, Kidney Drugs, Digestive System Drugs & Medicines, Laxatives.
Who are the key members and board of directors at Keron Lifesciences?
Board Members(5)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Shailesh Mishra | Director | 28-Feb-2016 | Current |
Manoj Jain | Director | 08-Dec-2022 | Current |
Ghazi Alabdulrazzak | Director | 28-Feb-2016 | Current |
Abdulmohsin Alabdulrazzaq | Director | 28-Feb-2016 | Current |
Ralph Dsouza | Director | 25-May-2021 | Current |
Financial Performance of Keron Lifesciences.
Keron Lifesciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 77.56% decrease. The company also saw a substantial improvement in profitability, with a 14.1% increase in profit. The company's net worth observed a substantial decline by a decrease of 25.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Keron Lifesciences?
In 2023, Keron Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Chattary Ajwan Infotech Private LimitedActive 17 years 10 months
Shailesh Mishra, Manoj Jain and 1 more are mutual person
- Aidline Healthcare Private LimitedActive 10 years 2 months
Shailesh Mishra, Manoj Jain and 2 more are mutual person
Charges (Loans)
Lender | Amount | Status |
---|---|---|
United Bank Of India Creation Date: 27 Jul 2013 | ₹1.75 Cr | Satisfied |
How Many Employees Work at Keron Lifesciences?
Keron Lifesciences has a workforce of 41 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Keron Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Keron Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.